3 hrs ago | GroundReport.com
Which companies are developing universal flu vaccines from what sources?
The Emerging Technologies Conference at M.I.T. ended a few days ago with a focus on developing universal flu vaccines.
7 hrs ago | PR-inside.com
NCKU Signed a MOU with ScinoPharm Taiwan on Nov. 24th
National Cheng Kung University , Taiwan signed a MOU with ScinoPharm Taiwan Ltd.
Novartis Deal Gives Incyte a Boost
As only the second JAK inhibitor to enter phase III trials, Incyte's INCB18424 has already attracted a fair amount of attention.
Ohio to get $5M under settlement with Aventis
Ohio will get $5 million as part of a global settlement with drug maker Sanofi-Aventis, which was accused of cheating Medicaid on the cost of nasal sprays.
CytRx to commence Phase II study of INNO-206 in advanced soft tissue sarcoma
Soft tissue sarcomas are cancers that are formed in the muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body.
The 2009 H1N1 influenza virus infection rates may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Inc.
Vioxx Trial Data Shows Early Cardiovascular Risk
Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug , could have been identified nearly four years before its manufacturer, Merck & Co.
Pfizer Increases R&D Commitment in China
Pfizer will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story.
Recalls: Check your boys clothing, gas ranges
The following recalls have been announced: - About 900 Electrolux ICON and Kenmore 30-inch PRO gas ranges made in Canada by Electrolux Home Products Inc., of Augusta, Ga., because an incorrect part allows more fuel to pass to the range's oven than can be burned efficiently.
Alnylam to Webcast Presentation at Piper Jaffray 21st Annual Health Care Conference
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the Piper Jaffray 21 st Annual Health Care Conference on Wednesday, December 2, 2009, at 8:00 a.m. ET at The New York Palace Hotel.
Inside Washington: Stream of WH health care visits
In this May 11, 2009 file photo, President Barack Obama , center, speaks about health care in the State Dining Room of the White House in Washington.
Human Genome Sciences seeks approval for Zalbin
Human Genome Sciences Inc. said Wednesday it has filed for marketing approval of its hepatitis C drug Zalbin.
Idera: Novartis deal ends, Merck pact extended
Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co.
QLT to pay US$20 million to settle suit launched by Massachusetts General Hospital
QLT Inc. has agreed to pay US$20 million to settle a legal dispute with Massachusetts General Hospital.
Johnson & Johnson unit's HIV drug approved
A division of Johnson & Johnson said Wednesday that federal regulators granted full approval to an HIV drug designed to treat patients who have stopped responding to other treatments.
GSK says still no answer on whether H1N1 vaccine batch triggers more reaction
The investigation into whether a batch of H1N1 vaccine may have triggered a higher-than-normal rate of allergic reactions hasn't yet come up with answers, vaccine manufacturer GlaxoSmithKline said Tuesday.
Merck says key Fosamax lawsuit dismissed
Merck & Co. on Tuesday said a U.S. district court dismissed claims against the company in a second key case alleging the osteoporosis drug Fosamax causes painful jaw bone destruction.
CDC Suit Over Privacy Dismissed
A lawsuit filed against the Centers for Disease Control and Prevention by a patient at the center of a 2007 tuberculosis scare has been dismissed.
Gilead, GlaxoSmithKline to commercialise Viread for chronic hepatitis B in Asia
The companies said that their combined commercialisation activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in most countries is greater than 8%. Under the terms of the deal, Gilead will retain exclusive rights for commercialisation of Viread for HBV in Hong Kong, Singapore, ...
CDC warns: Holiday could bring more swine flu
Let us give thanks - and pass the Purell. Your family might be sharing more than turkey and pumpkin pie this Thanksgiving.
Also on Topix